Literature DB >> 49178

Significance of plasma copper and caeruloplasmin concentrations in rheumatoid arthritis.

D P Bajpayee.   

Abstract

To understand the role of copper in initiating protein alterations in rheumatoid arthritis (RA) as reported previously, concentrations of copper anc caeruloplasmin were determined in RA patients. The mean copper concentration of the RA population examined was 24.8 mumol/l (157.5 mug/100 ml), and the mean caeruloplasmin concentration in this RA population was 45.52 mg/100 ml. These values are not different from those reported by previous workers. However, when the RA population was divided into three groups according to sex and oestrogen therapy it was found that caeruloplasmin and copper concentrations in the group of female RA patients on oestrogens was significantly different from other groups (P less than 0.001). A highly significant (P less than 0.01) positive correlation was obtained between copper and caeruloplasmin concentrations (r = 0.91). Concentrations of copper and caeruloplasmin failed to explain the low sulphydryl content of plasma which was observed to be independent of these two parameters. Increased alpha2-globulin concentration, which was refractory to chrysotherapy but 'finger-printed' with a pure preparation of caeruloplasmin in electrophoresis, along with the absence of Kayser-Fleischer rings, supports the contention that copper is not present in a free ionic state in RA patients. This study shows that only a concurrent oestrogen therapy raises copper and caeruloplasmin concentration significantly in a female RA population. Past investigators appear to have overlooked this fact, and it could be that a disproportionate sex distribution (more female rheumatoid arthritics) could cause misleading results in RA studies. The role of oestrogens, copper, and caeruloplasmin in causing exacerbation of RA symptoms is discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 49178      PMCID: PMC1006365          DOI: 10.1136/ard.34.2.162

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  SERUM SULFHYDRYL DETERMINATIONS AND SIGNIFICANCE IN CONNECTIVE TISSUE DISEASES.

Authors:  A LORBER; C M PEARSON; W L MEREDITH; L E GANTZ-MANDELL
Journal:  Ann Intern Med       Date:  1964-09       Impact factor: 25.391

2.  OESTROGEN: THE NATURAL STIMULANT OF BODY DEFENCE.

Authors:  T NICOL; D L BILBEY; L M CHARLES; J L CORDINGLEY; B VERNON-ROBERTS
Journal:  J Endocrinol       Date:  1964-10       Impact factor: 4.286

3.  WHOLE-BLOOD CONCENTRATIONS OF COPPER AND ZINC IN RHEUMATOID ARTHRITIS STUDIED BY ACTIVATION ANALYSIS.

Authors:  L O PLANTIN; P O STRANDBERG
Journal:  Acta Rheumatol Scand       Date:  1965

4.  Exchange of ceruloplasmin copper with ionic Cu64 with reference to Wilson's disease.

Authors:  I H SCHEINBERG; A G MORELL
Journal:  J Clin Invest       Date:  1957-08       Impact factor: 14.808

5.  A colorimetric method for determining low concentrations of mercaptans.

Authors:  G L ELLMAN
Journal:  Arch Biochem Biophys       Date:  1958-04       Impact factor: 4.013

6.  Reversible aggregation of serum albumin in the reaction with copper (II).

Authors:  H A SAROFF; W L CHOATE
Journal:  Arch Biochem Biophys       Date:  1958-03       Impact factor: 4.013

7.  Inborn errors of metabolism in neurology (Wilson's disease, Refsum's disease and lipidoses).

Authors:  J N Cumings
Journal:  Proc R Soc Med       Date:  1971-03

8.  Trace metal composition of synovial fluid and blood serum of patients with rheumatoid arthritis.

Authors:  W Niedermeier; J H Griggs
Journal:  J Chronic Dis       Date:  1971-01

9.  Serum copper levels in rheumatoid arthritis: relationship of elevated copper to protein alterations.

Authors:  A Lorber; L S Cutler; C C Chang
Journal:  Arthritis Rheum       Date:  1968-02

10.  Zinc and copper levels in pregnant women and those taking oral contraceptives. A preliminary report.

Authors:  J A O'Leary; W N Spellacy
Journal:  Am J Obstet Gynecol       Date:  1969-01-01       Impact factor: 8.661

View more
  15 in total

1.  Serum copper and caeruloplasmin in ankylosing spondylitis, systemic sclerosis, and morphea.

Authors:  M I Jayson; P Davis; J T Whicher; G Walters
Journal:  Ann Rheum Dis       Date:  1975-10       Impact factor: 19.103

2.  Letter: Significance of plasma copper and caeruloplasmin concentrations in rheumatoid arthritis.

Authors:  J R Sorenson; D DiTommaso
Journal:  Ann Rheum Dis       Date:  1976-04       Impact factor: 19.103

3.  Ambivalent role of copper in inflammatory disorders.

Authors:  M W Whitehouse
Journal:  Agents Actions       Date:  1976-02

4.  Serum copper and its relationship to clinical symptoms in rheumatoid arthritis.

Authors:  D H Brown; W W Buchanan; A F el-Ghobarey; W E Smith; J Teape
Journal:  Ann Rheum Dis       Date:  1979-04       Impact factor: 19.103

5.  Caeruloplasmin concentration and oxidase activity in polyarthritis.

Authors:  J S Dixon; M Greenwood; J R Lowe
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

Review 6.  Copper and zinc body levels in inflammation: an overview of the data obtained from animal and human studies.

Authors:  R Milanino; M Marrella; R Gasperini; M Pasqualicchio; G Velo
Journal:  Agents Actions       Date:  1993-07

7.  Serum copper and related variables in rheumatoid arthritis.

Authors:  P R Scudder; D Al-Timimi; W McMurray; A G White; B C Zoob; T L Dormandy
Journal:  Ann Rheum Dis       Date:  1978-02       Impact factor: 19.103

8.  Concerning the role of endogenous copper in the acute inflammatory process.

Authors:  R Milanino; A Conforti; M E Fracasso; L Franco; R Leone; E Passarella; G Tarter; G P Velo
Journal:  Agents Actions       Date:  1979-12

9.  Serum copper: a marker of disease activity in rheumatoid arthritis.

Authors:  A A Youssef; B Wood; D N Baron
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

Review 10.  Copper and inflammation--a possible rationale for the pharmacological manipulation of inflammatory disorders.

Authors:  R Milanino; A Conforti; L Franco; M Marrella; G Velo
Journal:  Agents Actions       Date:  1985-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.